B-type natriuretic peptide levels and insulin resistance in patients witn severe ischemic myocardial dysfunction

Journal of Endocrinological Investigation

Volumn 32, Issue 10, 2009, Pages 805-809

  Tassone, F ^a   Gianotti, L ^a   Rolfo, F ^a   Visconti, G ^a   Borretta, G ^a   Feola, M ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b Ospedale SS Trinita'   (Italy)

Author keywords

BNP; Ejection fraction; HOMA IR; Insulin resistance

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GLUCOSE; INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; B TYPE NATRIURETIC PEPTIDE BLOOD LEVEL; BODY MASS; CARDIAC PATIENT; DIABETES MELLITUS; DISEASE SEVERITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEX DIFFERENCE;

AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; CONSTRICTION, PATHOLOGIC; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOASSAY; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION;

EID: 77349089728     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03345749     Document Type: Article

References (32)

1. Doust J, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Fam Physician 2006, 74: 1893-8.
2. Feola M, Aspromonte N, Milani L, et al. Plasma brain natriuretic Peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern. J Card Fail 2008, 14: 420-5.
3. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998, 351: 9-13.
4. Kiemer AK, Hartung T, Vollmar AM. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. J Immunol 2000, 165: 175-81.
5. Weber NC, Blumenthal SB, Hartung T, Vollmar AM, Kiemer AK. ANP inhibits TNF-alpha-induced endothelial MCP-1 expression: involvement of p38 MAPK and MKP-1. J Leukoc Biol 2003, 74: 932-41.
6. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112: 1756-62.
7. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005, 90: 3622-8.
8. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005, 46: 660-6.
9. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115: 1345-53.
10. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006, 152: 1071-6.
11. St Peter JV, Hartley GG, Murakami MM, Apple FS. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006, 52: 680-5.
12. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005, 112: 2163-8.
13. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003, 26: 669-76.
14. Tekes S, Cikim AS. The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. J Hum Hypertens 2007, 21: 546-50.
15. Ybarra J, Planas F, Pou JM. Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study. Diab Vasc Dis Res 2008, 5: 19-24.
16. Celik O, Sahin I, Celik N, et al. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 2007, 22: 2992-8.
17. Genuth S, Alberti KG, Bennett P, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26: 3160-7.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-97.
19. Gardin JM, Adams DB, Douglas PS, et al; American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr 2002, 15: 275-90.
20. Sahn DJ, Demaria A, Kisslo J, Weyman A. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58: 1072-83.
21. Cerqueira MD, Weissman NJ, Dilsizian V, et al; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardised myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the Council of Clinical Cardiology of the American Heart Association. Circulation 2002, 105: 539-42.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
23. Johnston CI, Hodsman PG, Kohzuki M, Casley DJ, Fabris B, Phillips PA. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system: endogenous antagonists. Am J Med 1989, 87: 24S-8S.
24. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A 1996, 93: 12490-5.
25. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996, 97: 1916-23.
26. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110: 1103-7.
27. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002, 51: 1699-707.
28. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005, 54: 991-9.
29. Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 2003, 5: 214-22.
30. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41: 127-33.
31. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005, 90: 3622-8.
32. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365: 1415-28.